Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
25 oct. 2022 06h30 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523
01 déc. 2021 07h02 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Doses First Participants in Altitude Trial
22 nov. 2021 07h02 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...